← 產業報告目錄
Peptide–Drug Conjugates (PDCs) Market Size, Share & Trends Analysis Report Product Type (Radiopharmaceutical PDCs, Cytotoxic PDCs, Diagnostic PDCs, Emerging PDCs), By Therapeutic Application (Oncology, Neuroendocrine Tumors, Prostate Cancer, Solid Tumors, Hematologic Cancers, Neurological Disorders, Metabolic Diseases, Infectious Diseases), Type, Product, By Region, And By Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-02頁數 180報告編號 INSIGHTACE-68d46629ad
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 3.80 Bn as of 2024, the global Peptide–Drug Conjugates (PDCs) Market is projected to climb to USD 21.10 Bn by 2034, reflecting a compound annual growth rate of 18.8% over the 2025–2034 period.
At its core, Peptide–Drug Conjugates (PDCs) pertains to The emergence of Peptide–Drug Conjugates (PDCs) therapy for patients suffering from different cancers is believed to create several clinical opportunities during the forecast period. Stakeholders across the healthcare landscape are mountingly turning to these solutions to meet contemporary demands.
The market's upward path is driven by mounting healthcare spending, technological evolution, and the mounting focus on personalized and precision-based approaches in healthcare.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, driven by rapid industrialization and expanding end-user bases.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Peptide–Drug Conjugates (PDCs) Market Snapshot
Chapter 4. Global Peptide–Drug Conjugates (PDCs) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Global Peptide–Drug Conjugates (PDCs) Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on PEPTIDE–DRUG CONJUGATES (PDCS) MARKET Industry Trends
Chapter 5. Peptide–Drug Conjugates (PDCs) Market Segmentation 1: By Product Type, Estimates & Trend Analysis
5.1. Market Share By Product Type, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product Type:
5.2.1. Radiopharmaceutical PDCs
5.2.2. Cytotoxic PDCs
5.2.3. Diagnostic PDCs
5.2.4. Emerging PDCs
Chapter 6. Peptide–Drug Conjugates (PDCs) Market Segmentation 2: By Product, Estimates & Trend Analysis
6.1. Market Share By Product, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
6.2.1. OctreoScan
6.2.2. Lutathera
6.2.3. Pluvicto
6.2.4. Illuccix
6.2.5. Others
Chapter 7. Peptide–Drug Conjugates (PDCs) Market Segmentation 3: By Therapeutic Application, Estimates & Trend Analysis
7.1. Market Share By Therapeutic Application, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
7.2.1. Oncology
7.2.2. Neuroendocrine Tumors
7.2.3. Prostate Cancer
7.2.4. Solid Tumors
7.2.5. Hematologic Cancers
7.2.6. Neurological Disorders
7.2.7. Metabolic Diseases
7.2.8. Infectious Diseases
Chapter 8. Peptide–Drug Conjugates (PDCs) Market Segmentation 4: By Type, Estimates & Trend Analysis
8.1. Market Share By Type, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Vessel Type:
8.2.1. Therapeutic
8.2.2. Diagnostic
Chapter 9. Peptide–Drug Conjugates (PDCs) Market Segmentation 6: Regional Estimates & Trend Analysis
9.1. Global Peptide–Drug Conjugates (PDCs) Market, Regional Snapshot 2024 & 2034
1.1. North America
1.1.1. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
1.1.1.1. United States
1.1.1.2. Canada
1.1.2. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.1.3. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.1.4. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.1.5. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
1.2. Europe
1.2.1. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
1.2.1.1. Finland
1.2.1.2. UK
1.2.1.3. France
1.2.1.4. Germany
1.2.1.5. Netherland
1.2.1.6. Spain
1.2.1.7. Rest of Europe
1.2.2. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.2.3. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.2.4. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.2.5. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
1.3. Asia Pacific
1.3.1. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
1.3.1.1. China
1.3.1.2. Japan
1.3.1.3. South Korea
1.3.1.4. Rest of Asia Pacific
1.3.2. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.3.3. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.3.4. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.3.5. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
1.3.6. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by Cargo Ships, 2021-2034
1.4. Latin America
1.4.1. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
1.4.1.1. GCC Countries
1.4.1.2. Israel
1.4.1.3. South Africa
1.4.1.4. Rest of Middle East and Africa
1.4.2. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.4.3. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.4.4. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.4.5. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
1.5. Middle East & Africa
1.5.1. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
1.5.1.1. GCC Countries
1.5.1.2. Israel
1.5.1.3. South Africa
1.5.1.4. Rest of Middle East and Africa
1.5.2. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.5.3. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.5.4. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.5.5. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
Chapter 2. Competitive Landscape
2.1. Major Mergers and Acquisitions/Strategic Alliances
2.2. Company Profiles
2.2.1. Novartis AG
2.2.1.1. Business Overview
2.2.1.2. Key Product/Service
2.2.1.3. Financial Performance
2.2.1.4. Geographical Presence
2.2.1.5. Recent Developments with Business Strategy
2.2.2. AstraZeneca
2.2.3. Bicycle Therapeutics
2.2.4. Cybrexa Therapeutics
2.2.5. Esperance Pharmaceuticals
2.2.6. Oncopeptides AB
2.2.7. Pepgen Corporation
2.2.8. Soricimed Biopharma
2.2.9. Theratechnologies
2.2.10. Pfizer Inc
2.2.11. Validus Pharmaceuticals LLC
2.2.12. Antisense Therapeutics
2.2.13. Midatech Pharma PLC
2.2.14. Ipsen Pharma
2.2.15. Chiasma, Inc.
2.2.16. Peptron, Inc.
2.2.17. CRINETICS PHARMACEUTICALS
2.2.18. Dauntless Pharmaceuticals
2.2.19. Camurus AB
2.2.20. Teva Pharmaceuticals Inc.
2.2.21. Pharmaspur
2.2.22. Aspireo Pharmaceuticals
2.2.23. Ionis Pharmaceuticals Inc
2.2.24. Midatech Pharma Plc
2.2.25. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們